Skip to main content
Informational

Data use:

We use cookies and similar tools to make your use of this website easy and to keep it working properly. We may share data about you and how you use the site with third parties, such as analytics and marketing partners. Learn more in our Privacy Policy and Terms of Use. By continuing to use the site, you agree to this.

Drug Pipeline Insights Report

Fast action for postpartum depression

New drugs for postpartum depression, dermatitis and blindness are coming. 

New drugs focus on recent therapies for larger patient populations

Welcome to the next issue of Drugs to Watch for 2023

In this Drug Pipeline Insights Report, we review:

  • Fast-acting treatment for postpartum depression
  • The first treatment approved to prevent blindness due to geographic atrophy
  • Relief from moderate-to-severe atopic dermatitis

Download now

Don't want to read the full report? Download the brief summary.

View summary

Related Content

3 new first-in-class therapies coming

See how innovation is driving the latest product development.

Rules impacting pharmacy: Summer 2023 legislative sessions

Learn what's at stake as the Senate considers PBM legislation.

4 new drugs to watch this year

Breakthrough treatments for menopause, Alzheimer's and hemophilia are coming.